FluoSphera Licenses Debiopharm’s AbYlink™ Technology for 3D Antibody Characterization while Leveraging Leica Microsystems Viventis Deep Imaging Capabilities

Contributed by: Business Wire

Logo

Tags

Research

Environment

Climate Change

Infectious Diseases

Biotechnology

General Health

Pharmaceutical

Health

Science

Oncology

Debiopharm

More Like This

Debiopharm to Reveal Insights From Their ADC, DDR Inhibitor, and Antibody Conjugation Technology Research at the 2025 AACR Conference in Chicago

Debiopharm and Oncodesign Services Launch Strategic Collaboration to Propel Radiopharmaceuticals in Preclinical Research

Debiopharm and Genome & Company Reach Agreement for Potential First-In Class Oncology Antibody Drug Conjugate Family

Debiopharm Extends SunRock Biopharma Partnership for Antibody Drug Conjugates Targeting HER3 in EGFR Mutated Cancers

Debiopharm Licenses SunRock Biopharma’s Anti-HER3/HER2 Antibody to Explore the Full Potential of Bispecific ADC Debio 2512

Byondis to Present Data from its Novel ADC Technology Platforms at the American Society for Cancer Research Meeting 2026

Debiopharm to Unveil New Pre-Clinical and Clinical Research Advances in DDR Inhibition, Dual Payload ADCs, and AI-Driven Biomarkers at AACR 2026

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates